Applera Corp. 's July 24 announcement of a $75 million high-throughout genotyping initiative to be equally funded by its three businesses, Celera Genomics Group , Applied Biosystems Group (ABI), and Celera Diagnostics (a joint venture of Celera Genomics and ABI), coupled with its conference call two days later to discuss earnings, has provided a context for the company to begin to reveal its diagnostics strategy. New information about the structure of the joint venture, in which Celera Genomics is absorbing the short-term financial risk by covering the JV's initial operating losses, also sheds more light on the acceleration of Celera Genomics' business strategy as it moves away from an information-based genomics platform model toward that of a partnering-oriented pharmaceutical company. (See "The Proteomic Evolution of Celera, Incyte and Myriad," START-UP, June 2001 [A#2001900098.)
The new genotyping program is a way for Applera to further leverage the return on its human genome sequencing investment....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?